[{"address1": "50 rue de Dijon", "city": "Daix", "zip": "21121", "country": "France", "phone": "33 3 80 44 75 00", "website": "https://www.inventivapharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.", "fullTimeEmployees": 120, "companyOfficers": [{"maxAge": 1, "name": "Mr. Frederic  Cren", "age": 57, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 535081, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pierre  Broqua Ph.D.", "age": 61, "title": "Co-Founder, Chief Scientific Officer, Deputy CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 462124, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean  Volatier", "age": 59, "title": "Deputy GM & CFO", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alice  Roudot-Ketelers Pharm.D.", "age": 52, "title": "Chief Operating Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Duranson L.L.M.", "age": 49, "title": "General Counsel", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nathalie  Harroy", "age": 56, "title": "Head of Human Resources", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kristina  Meyer Ph.D.", "title": "Executive VP and Business Development & Alliance Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Cooreman", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pascaline  Clerc Ph.D.", "age": 43, "title": "Executive Vice President of Strategy & Corporate Affairs", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 5, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "open": 3.64, "dayLow": 3.64, "dayHigh": 3.64, "regularMarketOpen": 3.64, "regularMarketDayLow": 3.64, "regularMarketDayHigh": 3.64, "beta": 1.014, "forwardPE": -1.5555557, "volume": 200, "regularMarketVolume": 200, "bid": 2.18, "ask": 2.41, "marketCap": 190595872, "fiftyTwoWeekLow": 3.64, "fiftyTwoWeekHigh": 3.73, "priceToSalesTrailing12Months": 8.228462, "fiftyDayAverage": 3.64, "twoHundredDayAverage": 3.65005, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 216056272, "floatShares": 15499928, "sharesOutstanding": 52361500, "heldPercentInsiders": 0.20643, "heldPercentInstitutions": 0.52749, "bookValue": -0.616, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -110426000, "trailingEps": -2.64, "forwardEps": -2.34, "enterpriseToRevenue": 9.328, "enterpriseToEbitda": -2.121, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "IVEVF", "underlyingSymbol": "IVEVF", "shortName": "INVENTIVA SA", "longName": "Inventiva S.A.", "firstTradeDateEpochUtc": 1557235800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9a82baa4-4b3b-3869-951c-b996aa6dd954", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.64, "targetHighPrice": 24.84, "targetLowPrice": 6.56, "targetMeanPrice": 17.41, "targetMedianPrice": 19.88, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 27340000, "totalCashPerShare": 0.526, "ebitda": -101848000, "totalDebt": 54081000, "quickRatio": 0.858, "currentRatio": 0.961, "totalRevenue": 23163000, "revenuePerShare": 0.511, "returnOnAssets": -0.69187, "returnOnEquity": -16.42755, "freeCashflow": -42885000, "operatingCashflow": -81614000, "revenueGrowth": 0.073, "grossMargins": 0.95609003, "operatingMargins": -2.8842897, "financialCurrency": "EUR", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]